Avience Biomedicals Limited Announces Audited Financial Results for FY Ended March 31, 2026
Avience Biomedicals Limited has announced its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The company's Board of Directors approved the financial statements during a meeting held on July 16, 2026.The statutory auditors, Haribhakti & Co LLP, issued an unmodified audit opinion on the audited financial statements for the year ended March 31, 2026. The report confirms that the financial results provide a true and fair view of the company's financial position and performance in conformity with applicable accounting standards and principles generally accepted in India.
Financial Performance Overview
The company reported a significant increase in its consolidated net profit compared to the previous fiscal year. While the standalone profit for the period shows steady figures, the consolidated performance reflects the integrated results of the group, including DR Meditech Surgical & Diagnostics (India) Private Limited.The following table summarizes the consolidated financial performance:
| Particulars | Half Year (Mar 31, 2026) | Half Year (Sep 30, 2025) | Half Year (Mar 31, 2025) | Year Ended (Mar 31, 2026) | Year Ended (Mar 31, 2025) |
|---|---|---|---|---|---|
| Total Income | 2,591.63 | 2,687.87 | 2,492.63 | 5,279.50 | 4,590.84 |
| Total Expenses | 1,955.13 | 2,077.79 | 1,902.31 | 4,032.92 | 3,606.47 |
| Profit Before Tax | 636.50 | 610.08 | 590.33 | 1,246.58 | 984.18 |
| Tax Expense | 183.75 | 153.56 | 159.90 | 337.31 | 258.00 |
| Profit After Minority Interest | 421.50 | 453.78 | 426.89 | 875.28 | 709.90 |
All amounts are in Rs. Lakhs.
Assets and Liabilities
The company's consolidated balance sheet shows a substantial growth in shareholders' funds and assets compared to the previous year. The total assets of the group stood at Rs. 7,794.39 lakhs as of March 31, 2026.| Particulars | As at March 31, 2026 | As at March 31, 2025 |
|---|---|---|
| Equity and Liabilities | ||
| Shareholders' funds | 3,141.25 | 2,265.98 |
| Non-current liabilities | 1,357.48 | 1,023.68 |
| Current liabilities | 7,794.39 | 5,648.84 |
| Total Equity and Liabilities | 12,293.12 | 8,938.50 |
| Assets | ||
| Non-current assets | 1,307.12 | 1,005.40 |
| Current assets | 7,794.39 | 5,648.84 |
| Total Assets | 9,101.51 | 6,654.24 |
Note: Figures are presented in Rs. Lakhs.
Cash Flow Analysis
The consolidated statement of cash flows for the year ended March 31, 2026, shows a net decrease in cash and cash equivalents totaling Rs. 421.98 lakhs. This was primarily driven by investing activities and working capital changes.| Cash Flow Components | Year Ended March 31, 2026 | Year Ended March 31, 2025 |
|---|---|---|
| Net cash generated from operating activities | 339.43 | 406.41 |
| Net cash used in investing activities | (953.91) | (1,326.94) |
| Net cash generated from financing activities | (194.51) | 782.24 |
| Net decrease in cash and equivalents | (421.98) | 421.98 |
Operational Updates and Capital Expansion
Following the conclusion of the fiscal year, Avience Biomedicals Limited completed an Initial Public Offering (IPO) of 1,453,800 equity shares at an issue price of Rs. 208 per share. The company is listed on the SME Portal of the National Stock Exchange of India Limited (NSE EMERGE).The proceeds from this issuance are slated for:
- Financing capital expenditure for a new manufacturing unit located in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA) in Gautam Buddha Nagar, Uttar Pradesh.
- Funding working capital requirements.
- General corporate purposes.
AVIENCE Stock Price Movement
Avience Biomedicals Limited shares rallied by 0.82% on Thursday to settle at ₹277.5. Despite the gain, the stock plunged to its 52-week low of ₹268.5 during the session where 30,600 shares changed hands.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: